Hall E D, Travis M A
Central Nervous System Diseases Research Unit, Upjohn Company, Kalamazoo, MI 49001.
Brain Res. 1988 Jun 7;451(1-2):350-2. doi: 10.1016/0006-8993(88)90782-2.
The effects of the novel non-glucocorticoid 21-aminosteroid U74006F on arachidonic acid (AA)-induced vasogenic brain edema were examined in rats. Vasogenic edema was assessed in terms of the extent of Evan's blue extravasation after subcortical micro-injection of AA indicative of blood-brain barrier disruption. U74006F, given i.v. at 15 min before the AA, produced a dose-related reduction in the area of subsequent Evan's blue staining measured in a coronal brain cross-section through the injection site. The highest dose tested (1.0 mg/kg) resulted in a 65% decrease in the area of blood-brain barrier disruption in comparison to that seen in vehicle-treated animals (P less than 0.0001). The mechanism of the anti-edema effect of U74006F is discussed in relation to the previously demonstrated ability of the compound to inhibit oxygen free radical-mediated lipid peroxidation.